All amounts in U.S. dollars unless otherwise stated

TORONTO — Docebo Inc. (NASDAQ: DCBO; TSX:DCBO) (“Docebo” or the “Company”), a leading learning platform provider with a foundation in artificial intelligence (AI) and innovation, announced financial results for the three and nine months ended September 30, 2024. All amounts are expressed in US dollars unless otherwise stated.

Record Third Quarter Revenue of $36.3 Million up 23% YoY Self-Service Revenue rose 64% to $8.4 Million 200% Adjusted EBITDA Improvement YoY

Latham Group, Inc. (NASDAQ: SWIM), a prominent designer, manufacturer, and marketer of in-ground residential swimming pools, disclosed its financial outcomes for the fiscal third quarter concluded on September 28, 2024, in an 8-K filing with the Securities and Exchange Commission on November 5, 2024. In the third quarter, Latham Group posted net sales of $150.5 […]

Issuer Direct Corporation (NYSE American: ISDR) recently disclosed its operating results for the three and nine months ending on September 30, 2024. The press release outlined the company’s progress and financial standings during this period. Brian R. Balbirnie, the Chief Executive Officer of Issuer Direct, highlighted the company’s transitional achievements towards a more recurring revenue […]

TORONTO — Softchoice Corporation (“Softchoice” or the “Company”) (TSX: SFTC), a leading software- and cloud-focused IT solutions provider, today announced its financial results for the third quarter (“Q3 2024”) ended September 30, 2024. Softchoice will hold a conference call/webcast to discuss its results today, November 8, 2024, at 8:30 a.m. ET. Unless otherwise noted, all dollar ($) amounts are in U.S. dollars.

Record quarterly operating cash flow of $49 million and year to date operating cashflow of $103 million, an increase of 66% from the prior year period

Jasper Therapeutics, Inc., known for its innovative biotechnology focusing on developing treatments for mast cell-driven diseases, released its financial results for the quarter ended September 30, 2024, along with a corporate update. The company, a clinical-stage biotechnology firm, showcased significant advancements in its mast cell development programs, specifically highlighting positive initial data from its SPOTLIGHT […]